Denali Therapeutics Inc. DNLI Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $103.85M-10.7% | $97.91M-1.9% | $101.95M+3.8% | $102.7M+12.4% | $116.23M+8.6% | ||
| $33.51M+14.2% | $39.46M+31.3% | $35.48M+42.2% | $32.27M+28.1% | $29.35M+16.3% | ||
| $137.36M-5.6% | $137.37M+5.8% | $137.43M+11.6% | $134.96M+15.8% | $145.58M+10.1% | ||
| $137.36M-5.6% | $137.37M+5.8% | $137.43M+11.6% | $134.96M+15.8% | $145.58M+10.1% | ||
| -$137.36M+5.6% | -$137.37M-5.8% | -$137.43M-11.6% | -$134.96M-15.8% | -$145.58M-23.7% | ||
| $8.91M-29.3% | $8.92M-41.2% | $10.53M-34.2% | $10.84M-38.3% | $12.61M-20.8% | ||
| -$128.45M+3.4% | -$128.55M-12.0% | -$126.9M-18.4% | -$124.12M-25.3% | -$132.97M-30.6% | ||
| -$0.69+11.5% | -$0.73-7.4% | -$0.74-17.5% | -$0.72-22.0% | -$0.78-14.7% | ||
| -$0.69+11.5% | -$0.73-7.4% | -$0.74-17.5% | -$0.72-22.0% | -$0.78-14.7% | ||
| 186.6M+9.0% | 172.6M+5.0% | 172.4M+1.7% | 171.4M+1.6% | 171.2M+14.6% | ||
| 186.6M+9.0% | 172.6M+5.0% | 172.4M+1.7% | 171.4M+1.6% | 171.2M+14.6% | ||
| -$129.81M+2.4% | -$128.97M-9.1% | -$126.74M-28.0% | -$125.22M-24.7% | -$132.95M-28.2% | ||
| $8.91M-29.3% | $8.92M-41.2% | $10.53M-34.2% | $10.84M-38.3% | $12.61M-20.8% | ||
| -$1.36M-8,124% | -$419K— | $162K-98.0% | -$1.1M+19.4% | $17K+101% | ||
| -$137.36M+5.6% | -$137.37M-5.8% | -$137.43M-11.6% | -$134.96M-15.8% | -$145.58M-23.7% | ||
| -$134.51M+6.1% | -$134.5M-5.1% | -$134.49M-10.8% | -$131.92M-15.1% | -$143.26M-24.0% | ||
| -$134.51M+6.1% | -$134.5M-5.1% | -$134.49M-10.8% | -$131.92M-15.1% | -$143.26M-24.0% | ||
| -$137.36M+5.6% | -$137.37M-5.8% | -$137.43M-11.6% | -$134.96M-15.8% | -$145.58M-23.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Denali Therapeutics Inc.'s income statement data come from?
- Every line is extracted from Denali Therapeutics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.